- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04443686
5-aminolevulinic Acid In Advanced Malignancies
A Phase I Dose Finding Study Of Low-dose Radiation With Sensitization Using 5-aminolevulinic Acid In Advanced Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Anthony Olszanski, MD
- Phone Number: 2152141676
- Email: anthony.olsanski@fccc.edu
Study Contact Backup
- Name: Thomas Galloway, MD
- Phone Number: 2157285536
- Email: thomas.galloway@fccc.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Recruiting
- Fox Chase Cancer Center
-
Contact:
- Anthony Olszanski, MD
- Phone Number: 215-214-1676
- Email: anthony.olszanski@fccc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis:
- Patients must have a histologically and/or cytologically confirmed primary solid tumors
- Lesion(s) of interest (target or non-target) must be evaluable by PET or MRI
- Radiographic or clinical evidence of advanced/metastatic disease that is:
i. Resistant to standard therapy or for which no standard therapy is available.
Patient must be a candidate for, and be willing to undergo, PET/MRI imaging
- Patients who refuse MRI imaging are not eligible
- Patients who cannot undergo PET/MRI imaging will be deemed screen failures. Rescreening X1 (once) is permissible if the investigator feels that appropriate premedications may allow successful imaging.
All previous therapies for cancer, including radiotherapy, major surgery, and/or investigational therapies, must be discontinued for ≥ 14 days (≥ 28 days for mitomycin C or nitrosoureas ) before the treatment date, and all acute effects of any prior therapy must have resolved to baseline severity or Grade ≤ 1 Common Terminology Criteria for Adverse Events (CTCAE v5), except alopecia or parameters defined in this eligibility list
a. Patients previously treated with a bleomycin regimen are not permitted to undergo radiation therapy to the thorax
- Age ≥ 18 years
- ECOG performance status ≤ 2
- Systolic blood pressure ≥ 110 mmHg and diastolic blood pressure ≥ 70 mmHg
Adequate organ and marrow function as defined below:
- Absolute neutrophil Count ≥1,000/mm3 without growth factor use ≤ 7 days prior to C1D1
- Platelets ≥75,000/mm3 without platelet transfusion ≤ 7 days prior to C1D1
- Hemoglobin >8.0 mg/dL without red blood cell transfusion ≤ 7 days prior to C1D1
- Total serum bilirubin <1.5 X upper limit of normal (ULN)
- AST (SGOT)/ALT (SGPT) ≤2 X ULN
- Serum creatinine ≤ 1.5 X ULN AND Creatinine clearance (per eGFR) ≥ 40 mL/min/1.73 m2)
- Serum pregnancy test (for females of childbearing potential) negative within ≤7 days of C1D1
- Ability to understand and the willingness to sign a written informed consent document and comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.
- Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.
Exclusion Criteria:
1. Patients with symptomatic brain metastases are excluded. Patients with asymptomatic and treated CNS metastases may participate in this trial. The patient must have completed any prior treatment for CNS metastases ≥ 28 days prior to study entry, including radiotherapy or surgery. Steroids for the treatment of symptoms of brain metastasis are not permitted.
2. Patients must be able to take enterally-administered medications. Patients must not have any clinical evidence of impaired gastrointestinal function or any gastrointestinal disease that may significantly alter the absorption of ALA, in the opinion of the treating investigator. Patients who cannot swallow but rely on enterally-administered supplementation may enroll if they otherwise meet this criterion.
3. Current active treatment in another therapeutic clinical study 4. Active bacterial, fungal or viral infection, including hepatitis B (HBV) or hepatitis C (HCV) , requiring treatment with intravenous antibiotic, anti-fungal, or anti-viral medications (testing is not required for eligibility).
a. Patients may be enrolled while undergoing treatment for trivial infections with oral agents (e.g. superficial skin infections, uncomplicated urinary tract infections, candidal oral/vaginal infections, conjunctivitis, etc) 5. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)- related illness (testing is not required for eligibility) 6. Patients undergoing phototherapy for another, non-oncologic or oncologic disease (e.g. PUVA therapy or photodynamic therapy for skin diseases) 7. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
8. Patients with a known history of porphyria (testing for porphyria is not required to participate).
9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.
10. Patients with implanted battery-controlled devices (including, but not limited to, pacemakers and implanted cardiovascular defibrillator (AICDs)) that may suffer interference from neutron contamination of high energy photon beams.
11. Pregnant or breast-feeding patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ALA / Fractions of Radiotherapy
Subjects will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle.
Only one cycle per patient is allowed.
|
Patients will be seen in the CRU and administered ALA on day 1, 8, and 15.
Open-field radiotherapy and targeted-field radiotherapy will be given on days 1, 8, and 15
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Max tolerated dose (MTD) of ALA and radiation
Time Frame: 56 days
|
Determine the MTD of ALA and radiotherapy when administered concurrently
|
56 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of adverse events and laboratory abnormalities
Time Frame: 56 days
|
Overall safety profile of ALA with RT as characterized by type, frequency, severity, timing and relationship to study therapy of adverse events (AEs) and laboratory abnormalities as per CTCAE v5.0
|
56 days
|
Response rate
Time Frame: 1 year
|
Objective tumor response, as assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 in patients with measurable disease
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-1009 (Other Identifier: IRB)
- RT-90 (Other Identifier: FCCC ISRU)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on Low dose radiation and ALA
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Kyoung Ho Lee, MDSeoul National University Bundang Hospital; Ministry of Health & Welfare, Korea and other collaboratorsCompleted
-
Ohio State University Comprehensive Cancer CenterVarian Medical SystemsActive, not recruitingPneumonia | Covid-19 | Sars-CoV2United States, Colombia
-
All India Institute of Medical Sciences, New DelhiUnknown
-
Jiangsu Cancer Institute & HospitalZhongda Hospital; Central South University; Nanjing Chest Hospital; The Affiliated...Not yet recruitingCOVID-19 Pneumonia
-
Seoul National University HospitalSamsung Medical Center; SMG-SNU Boramae Medical Center; Korea Hydro & Nuclear...RecruitingKnee OsteoarthritisKorea, Republic of
-
British Columbia Cancer AgencyUnknown
-
University of Erlangen-Nürnberg Medical SchoolJohann Wolfgang Goethe University HospitalRecruitingOsteoarthritis | ArthrosisGermany
-
Korea Cancer Center HospitalTerminatedUterine Cervical NeoplasmsKorea, Republic of